Aardvark Therapeutics, Inc.

Contributing Author

Recent Articles by Aardvark Therapeutics, Inc.

Aug-11	Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates AARD AARD -8.62% GlobeNewswire
May-14	Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold AARD AARD -32.10% GlobeNewswire
May-07	Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates AARD GlobeNewswire
Mar-23	Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates AARD AARD -7.26% GlobeNewswire
Feb-27	Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome AARD AARD -56.20% GlobeNewswire
Feb-13	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AARD GlobeNewswire
Feb-12	Aardvark Therapeutics Announces Leadership Appointments AARD GlobeNewswire
Feb-12	Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer AARD GlobeNewswire
Feb-10	Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome AARD -6.45% GlobeNewswire
Dec-10	Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome AARD AARD +11.66% GlobeNewswire
Nov-25	Aardvark Therapeutics to Present at Upcoming Investor Conferences in December AARD GlobeNewswire
Nov-13	Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates AARD AARD -8.66% GlobeNewswire
Nov-11	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) AARD +5.94% GlobeNewswire
Nov-04	Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 AARD -5.68% AARD +7.14% GlobeNewswire
Nov-03	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) AARD GlobeNewswire
Nov-03	Aardvark Therapeutics to Present at Upcoming Investor Conferences in November AARD GlobeNewswire
Oct-22	Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek AARD -8.28% GlobeNewswire
Oct-08	Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome AARD GlobeNewswire
Sep-23	Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum AARD AARD +6.38% GlobeNewswire
Sep-04	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) AARD GlobeNewswire
Aug-27	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September AARD -5.67% AARD -5.56% GlobeNewswire
Aug-13	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates AARD +11.55% GlobeNewswire
Aug-12	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy AARD -9.96% GlobeNewswire
Jul-18	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) AARD GlobeNewswire
Jun-24	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference AARD +18.23% GlobeNewswire
May-19	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions AARD +5.46% AARD +5.47% GlobeNewswire
May-14	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights AARD -13.81% GlobeNewswire
May-07	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May AARD GlobeNewswire

Aardvark Therapeutics, Inc.

Recent Articles by Aardvark Therapeutics, Inc.

Upgrade your Finviz experience